1,25-Dihydroxyvitamin D3 as Well as Its Analogue OCT Lower Blood Calcium Through Inhibition of Bone Resorption in Hypercalcemic Rats with Continuous Parathyroid Hormone–Related Peptide Infusion
Authors:
Open Access
- 1 January 2000
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 15 (1) , 175-181
Abstract
The effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and its analogue 22-oxa-1,25(OH)2D3 (22-oxacalcitriol) (OCT) on calcium and bone metabolism were examined in an animal model of hypercalcemia with continuous infusion of parathyroid hormone–related peptide (PTHrP), to determine whether active vitamin D could counteract the skeletal action of PTHrP in addition to its reported effect in suppressing the production of PTHrP in cancer cells. Parathyroid glands were removed from 8-week-old Sprague–Dawley rats to eliminate the confounding effects of endogenous PTH. Animals were then continuously infused with human PTHrP(1–34) at a constant rate via osmotic minipumps for 2 weeks, and at the same time treated orally or intravenously with OCT or 1,25(OH)2D3 four to nine times during the 2-week period. Under these conditions, OCT and, surprisingly, 1,25(OH)2D3 alleviated hypercalcemia in a dose-dependent manner. 1,25(OH)2D3 and OCT suppressed the urinary excretion of deoxypyridinoline, although they did not affect renal calcium handling, suggesting that the antihypercalcemic effect is attributable to the inhibition of bone resorption. These active vitamin D compounds also counteracted the effects of PTHrP at the proximal renal tubules, as reflected by a decrease in phosphate excretion. Histomorphometric analysis of bone revealed a dose-related decrease in parameters of bone resorption. These results suggest that 1,25(OH)2D3 as well as OCT has the potential to alleviate hypercalcemia, at least in part, through the inhibition of bone resorption in hypercalcemic rats with constant PTHrP levels. We propose that the main function of active vitamin D in high bone-turnover states is to inhibit bone resorption, and this may have important implications for the understanding of the role of active vitamin D in the treatment of metabolic bone diseases, such as osteoporosis.Keywords
This publication has 19 references indexed in Scilit:
- Effect of Combination Treatment with a Vitamin D Analog (OCT) and a Bisphosphonate (AHPrBP) in a Nude Mouse Model of Cancer-Associated HypercalcemiaJournal of Bone and Mineral Research, 1998
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated ratsJournal of Bone and Mineral Research, 1996
- A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.Journal of Clinical Investigation, 1993
- The Role of the Vitamin D Endocrine System in Health and DiseaseNew England Journal of Medicine, 1989
- Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committeeJournal of Bone and Mineral Research, 1987
- Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chlorideThe American Journal of Medicine, 1987
- Synthetic studies of vitamin D3 analogues. VIII Synthesis of 22-oxavitamin D3 analogues.Chemical and Pharmaceutical Bulletin, 1986
- Biochemical Evaluation of Patients with Cancer-Associated HypercalcemiaNew England Journal of Medicine, 1980
- 1,25-Dihydroxycholecalciferol: A Potent Stimulator of Bone Resorption in Tissue CultureScience, 1972